Kendall Brown
Payments from drug & device makers
Across 196 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$601
- AbbVie$489
- Neurocrine Biosciences, Inc.$363
- Teva Pharmaceuticals USA, Inc.$284
- Vanda Pharmaceuticals Inc.$170
- plus $719 from 8 others
What the payments were for
- Food & beverage$3,73696%
- Education$1394%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 64 | $1,250 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $601 |
| AbbVie | 30 | $489 |
| Neurocrine Biosciences, Inc. | 20 | $363 |
| Teva Pharmaceuticals USA, Inc. | 12 | $284 |
| Vanda Pharmaceuticals Inc. | 8 | $170 |
| Johnson & Johnson | 9 | $165 |
| Alkermes, Inc. | 9 | $155 |
| Lundbeck LLC | 9 | $154 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| Noven Therapeutics, LLC | 3 | $47 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Indivior Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $19 |
How this compares
$3,875 in reported general payments places this provider in the 90th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 40 | $124,034 |
| Abilify MaintenaAripiprazole | 45 | $111,603 |
| AristadaAripiprazole Lauroxil | 23 | $76,334 |
| VraylarCariprazine Hcl | 46 | $74,165 |
| RexultiBrexpiprazole | 19 | $27,192 |
| Lurasidone Hcl | 54 | $10,511 |
| Aripiprazole | 85 | $2,765 |
| Quetiapine Fumarate | 177 | $2,597 |
| Duloxetine Hcl | 113 | $2,103 |
| Guanfacine Hcl ErGuanfacine Hcl | 21 | $2,017 |
| Lamotrigine | 123 | $1,553 |
| Clozapine | 17 | $1,335 |
| Olanzapine OdtOlanzapine | 41 | $1,267 |
| Ziprasidone Hcl | 15 | $1,258 |
| Trazodone Hcl | 67 | $1,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,250 | $138,79564 claims |
| Johnson & JohnsonInvega Sustenna | $165 | $124,03440 claims |
| Alkermes, Inc.Aristada | $155 | $76,33423 claims |
| AbbVieVraylar | $489 | $74,16546 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,460 family providers in Utah.
Other family in Logan
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.